Genotoxicity and Cytotoxicity of novel 10B carrier ((2R)-4,5,6-trihydroxy-2-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)boronic acid

Akan, Zafer; Özdemir, Hülya; Oto, Gökhan; Deniz, Sabahattin; Kaçar, Ömer; Başak, Ali Sadi; Çakır, Tahir; Sinav, Hatice Uslu; Demir, Göksel

doi:10.17546/msd.21367

Cited by 3 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pH was gradually increased from pH:3 to pH:7 and stabilised at a physiologic pH (pH:7.4). The 10BDG complexation reaction was tested using a Fourier Transform Infrared Attentuated Total Reflectance spectroscopy (FT-IR/ATR), as previously described (12). An aqueous solution of the BDG complex was prepared at a concentration of 250 mg/ml (21.28 mg 10B/ml).…”

Section: Methodsmentioning

confidence: 99%

“…An aqueous solution of the BDG complex was prepared at a concentration of 250 mg/ml (21.28 mg 10B/ml). In previous studies, the calculated non-toxic dose was about 30 mg BDG /kg and this dose was used for BNCT applications in Copenhagen Rats (12,15).…”

Section: Methodsmentioning

confidence: 99%

“…Our study group have newly developed a novel 10B carrier (2R)-4,5,6-trihydroxy-2-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)boronic acid (BDG). Biodistrubiton analyse result has shown that that 10B succesfully and specifically accumulated in the tumor tissue by the 10BDG and had also antiproliferative and antiapoptotic effects against tumor cells (12,13). In the present in vivo study, we assessed the efficacy of BDG as a novel 10B carrier and the success of BNCT application by using BDG in prostate cancer (PCa) model in rats.…”

Section: Introductionmentioning

confidence: 97%

See 2 more Smart Citations

The treatment of metastatic prostate carcinoma with BNCT in the ITU TRIGA MARKII reactor on rat model

Akan¹,

Özdemir²,

Oto³

et al. 2016

Medical Science and Discovery

Self Cite

View full text Add to dashboard Cite

Objective: The delivery of curative radiotherapy is commonly has the potential of serious side effects. These side effects still remain dose-limiting factor for external beam radiotherapy and as also curative treatment of prostate cancer (PCa). New treatment alternatives, such as BNCT, are investigated to eliminate these limitations and to improve the therapeutic efficiency of radiation on tumour cells including prostate cancer. In this study, we investigated the efficiency of BNCT application by using our novel 10B carrier that was called as 10B-DG on PCa using an in vivo mouse xenograft model. Material and Methods:PCa bearing Copenhagen rats (CRs) were used in this experimental animal study. A total of 12 CRs at the age of 2 months were used in this experimental animal study. MAT-LyLu PCa cells were injected subcutaneously into the peritoneal cavity of rats to create PCa model. The samples were divided into 4 groups: As, control, neutron irradiated, 10B-DG and 10B-DG + neutron irradiated group. 10BDG was administrated to tumour bearing rats and rats were exposed to 8.074 gy/hr thermal and epithermal. Tumour sizes were regularly measured by microtome and PET scan along 20 days. Results:The results have shown that the tumor growth were regressed just in 10B-DG + neutron irradiated group. In addition that, PET-CT scan results revealed that 18FDG uptake was stopped in the BNCT treated group due to metabolic inactivation of ablated tumor tisue. Conclusion:This study revealed that BNCT treatment can be successfully performed by using our novel 10B carrier 10BDG in the management of PCa. We suppose that this novel 10B carrier can take place as a safe and effective agent in routine clinical practice of BNCT.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 97%

See 1 more Smart Citation

The treatment of metastatic prostate carcinoma with BNCT in the ITU TRIGA MARKII reactor on rat model

Akan¹,

Özdemir²,

Oto³

et al. 2016

Medical Science and Discovery

Self Cite

View full text Add to dashboard Cite

show abstract

“…In previous study 3 to 18 F-DG was determined with Triple Quad LC/MS and shown to be an alternative boron carrier to BPA by in-vitro comparison studies (6,7,8).…”

Section: Introductionmentioning

confidence: 99%

Synthesis of Borono Fluoro Deoxy D glucose (10B-18F-DG) as Boron carrier for Boron neutron capture therapy BNCT

Akan¹,

Ozel²,

Oto³

et al. 2017

Medical Science and Discovery

Self Cite

View full text Add to dashboard Cite

Cellular uptake evaluation of pentagamaboronon-0 (PGB-0) for boron neutron capture therapy (BNCT) against breast cancer cells

et al. 2019

View full text Add to dashboard Cite

Genotoxicity and Cytotoxicity of novel 10B carrier ((2R)-4,5,6-trihydroxy-2-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)boronic acid

Cited by 3 publications

References 38 publications

The treatment of metastatic prostate carcinoma with BNCT in the ITU TRIGA MARKII reactor on rat model

The treatment of metastatic prostate carcinoma with BNCT in the ITU TRIGA MARKII reactor on rat model

Synthesis of Borono Fluoro Deoxy D glucose (10B-18F-DG) as Boron carrier for Boron neutron capture therapy BNCT

Cellular uptake evaluation of pentagamaboronon-0 (PGB-0) for boron neutron capture therapy (BNCT) against breast cancer cells

Contact Info

Product

Resources

About